News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
242,717 Results
Type
Article (20425)
Company Profile (107)
Press Release (222185)
Section
Business (78201)
Career Advice (800)
Deals (12400)
Drug Delivery (66)
Drug Development (24790)
Employer Resources (135)
FDA (4756)
Job Trends (6366)
News (121472)
Policy (9900)
Tag
Academia (1520)
Africa (379)
Alliances (22768)
Alzheimer's disease (506)
Antibody-drug conjugate (ADC) (41)
Approvals (4714)
Arizona (51)
Artificial intelligence (49)
Asia (27703)
Australia (3740)
Bankruptcy (52)
Best Places to Work (4943)
Biosimilars (40)
Biotechnology (67)
C2C Services and Suppliers (21908)
California (635)
Canada (340)
Cancer (205)
Career advice (708)
Cell therapy (55)
China (77)
Clinical research (18770)
Collaboration (87)
COVID-19 (1030)
Data (116)
Diabetes (37)
Diagnostics (2585)
Diversity, equity & inclusion (37)
Drug pricing (37)
Earnings (19843)
Employer resources (114)
Europe (35658)
Events (33252)
Executive appointments (83)
FDA (4822)
Florida (80)
Funding (66)
Gene therapy (41)
Georgia (31)
GLP-1 (284)
Government (1439)
Healthcare (5630)
Hotbed/Location (150479)
Illinois (76)
Indiana (60)
Infectious disease (1043)
Inflammatory bowel disease (49)
Interviews (110)
IPO (4725)
Job creations (1470)
Job search strategy (630)
Kansas (30)
Layoffs (140)
Legal (1992)
Lung cancer (55)
Management (39)
Manufacturing (42)
Maryland (115)
Massachusetts (492)
Medical device (3388)
Medtech (3392)
Mergers & acquisitions (7709)
Metabolic disorders (127)
Michigan (53)
Minnesota (92)
Neuroscience (585)
New Jersey (222)
New York (264)
NextGen Class of 2024 (2197)
Non-profit (1692)
North Carolina (222)
Northern California (312)
Obesity (87)
Ohio (37)
Opinion (86)
Pennsylvania (116)
People (28791)
Phase I (5371)
Phase II (7810)
Phase III (7330)
Pipeline (39)
Policy (31)
Postmarket research (754)
Preclinical (2764)
Press Release (62)
Rare diseases (53)
Real estate (2894)
Recruiting (51)
Regulatory (6772)
Reports (32)
Research institute (1302)
Resumes & cover letters (105)
South America (460)
Southern California (230)
Startups (2183)
Texas (77)
United States (2838)
Vaccines (146)
Washington State (57)
Weight loss (79)
Date
Today (44)
Last 7 days (253)
Last 30 days (829)
Last 365 days (14781)
2024 (10353)
2023 (15602)
2022 (20540)
2021 (22100)
2020 (20375)
2019 (17522)
2018 (12871)
2017 (12835)
2016 (12426)
2015 (13865)
2014 (10339)
2013 (8912)
2012 (9433)
2011 (9729)
2010 (9036)
242,717 Results for "axovant sciences ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders
Lobe Sciences Ltd., a biopharmaceutical company focused on developing transformative medicines to treat rare diseases and Clearway Global, LLC, a wholly owned subsidiary of Sancilio & Company, a pharmaceutical services company focused on value creation strategies, are pleased to announce a change in control of the Company and several enhancements to its ongoing growth strategy.
May 21, 2024
·
5 min read
Business
StageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational Update
StageZero Life Sciences announced its first quarter financial results for the three months ended March 31, 2024, and will provide an update on its business operations.
May 17, 2024
·
4 min read
Press Releases
ReWalk Robotics Ltd. Finalizes Corporate Name Change to Lifeward Ltd.
September 12, 2024
·
4 min read
Deals
Specac, Ltd Acquires Harrick Scientific
Specac, Ltd announced today the acquisition of Harrick Scientific, Inc.
April 2, 2024
·
3 min read
Press Releases
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
September 12, 2024
·
2 min read
Business
Mid-Atlantic BioTherapeutics, Inc. and SMITM Capital Markets Ltd enter into a significant financing agreement
SMITM CAPITAL MARKETS LTD, has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT), a clinical-stage ready US biopharmaceutical company.
June 19, 2024
·
4 min read
Lobe Sciences Announces Update - June 04, 2024
Lobe Sciences Ltd., a biopharmaceutical company focused on developing transformative medicines to treat diseases with unmet medical needs and rare diseases announced the evaluation of strategic alternatives to improve shareholder value.
June 4, 2024
·
5 min read
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, announces that its subsidiary, BioStrand, has been honored with the prestigious 2024 Impact Award, sponsored by InterSystems.
June 12, 2024
·
5 min read
Business
Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors
Lobe Sciences Ltd. today announced that Frederick D. Sancilio Ph.D. has agreed to join its Board of Directors.
May 31, 2024
·
6 min read
Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.
July 1, 2024
·
5 min read
1 of 24,272
Next